Kornimate/medical-research-clean huggingface dataset:
proteomic characterization of aggressive oligodendrogliomas

Conditions: Oligodendroglioma

Summary: oligodendrogliomas represent a distinct subgroup of adult gliomas characterized by specific molecular alterations (1p/19q codeletion, mutations of idh, tert promoter, cic, fubp1). these tumors account for 5 to 10% of adult gliomas and are of special relevance in the neuro-oncology field because of their frequent chemosensitivity (louis et al. 2016). the genetics of oligodendrogliomas is relatively well characterized but the mechanisms of oncogenesis for these tumors are poorly understood. although oligodendrogliomas prognosis is usually better than that of other adult glioma subtypes, it remains heterogeneous and there is no effective treatment at recurrence after radiotherapy and chemotherapy. our recent work conducted within the inca-funded national pola network has related this clinical heterogeneity to inter-tumoral heterogeneity. based on a transcriptomic analysis of a large series of oligodendroglial gliomas we identified 3 subgroups, the most aggressive group being characterized by aggressive clinical and molecular pattern. recent studies, however, have shown a relatively low level of concordance between mrna and protein expression, emphasizing the need to use proteomic-based approaches to better understand tumor biology. taking advantage of the pola cohort, we propose to expand our previous analysis by integrating a proteomic analysis of oligodendrogliomas. the aim of this project is to identify drivers of oligodendroglioma subgroups, among which potential druggable targets (i.e receptors, metabolism effectors). for this purpose, the proteomic profiles of 90 oligodendrogliomas will be generated and integrated with transcriptomic, genomic and methylation profiles in order to identify signaling pathways specifically associated with each subtype, especially with the most aggressive one. associations will be explored between candidate signaling pathways expression and clinical outcomes (survival, progression-free survival, objective response). the relevance of the 2 most promising candidate signaling pathways will be assessed in vitro and in vivo using genetically relevant mouse and xenograft models. our project will identify targetable oncogenic pathways associated with poor prognosis that could lead to new therapeutic strategies.


Eligibility criteria:
inclusion criteria: * - transcriptomic (microarray) data available or possible to obtain them, * methylation (450k) data available or possible to obtain them, * genomic (snp array) data available or possible to obtain them, * sufficient material for proteomic analysis (frozen tumor samples) exclusion criteria: * opposed patients

Keywords: oligodendroglioma proteomic analysis pola network
hypnosis: a path to appeasement

Conditions: Hematologic Cancer

Summary: hypnosis is a technique allowing the patient to focus his mental attention on a thought or a sensation, with the aim of reducing or modulating the intensity of a negative feeling or an ordeal encountered during the course of treatment. this tool can be used when patients are faced with chronic disorders (pain, anxiety, ...) or iatrogenic effects (nausea, asthenia, ...). the patient is referred to hypnosis care by the doctor, psychologist or paramedics who follow him, when they detect a need. several scientific studies have shown the effectiveness of hypnosis in improving the quality of life of patients with breast cancer and in reducing pain during invasive procedures. on the other hand, in hematology, no research has measured the evolution of anxiety, over time, in patients receiving hypnotherapy.


Eligibility criteria:
inclusion criteria: * patients over 18 years old, fluent in french. * patients starting hypnotherapy for anxiety disorders. * anxiety score on the hads scale (hospital anxiety and depression scale) greater than or equal to 8/21 * patients with diffuse large cell b-cell lymphoma or follicular lymphoma, whatever the stage of the disease. * diagnosis announcement less than 2 months old exclusion criteria: * persons deprived of their liberty by a judicial or administrative decision * adults subject to a legal protection measure

Keywords: hypnosis diffuse large cell b-cell lymphoma follicular lymphoma anxiety
intravitreal ranibizumab to treat macular edema after panretinal photocoagulation (phase ii)

Conditions: Proliferative Diabetic Retinopathy; Macular Edema

Summary: this is a randomized, open-label phase ii study evaluating the safety and efficacy of intravitreally administered ranibizumab 0.5mg in subjects with proliferative diabetic retinopathy experiencing post- panretinal photocoagulation (prp) macular edema.

levels of vegf are elevated in eyes wth diabetic macular edema and the expression of vegf was found to be elevated temporarily following the photocoagulation of human retinal pigment epithelial (rpe) cells. ranibizumab (lucentis tm, genentech) is an anti-vegf antibody shown to have properties to prevent macular edema. we hypothesize that vegf inhibition can effectively treat prp-induced macular edema, thereby minimizing post-prp vision loss. subjects who meet eligibility criteria will receive 0.5mg ranibizumab administered 7-14 days post-prp. additional intravitreal injections of 0.5 mg of ranibizumab at day 30 and/or day 60 may be also be administered. all subjects will be followed for 90 days for safety and efficacy assessments. there is no placebo or sham arm of this trial.

Eligibility criteria:
inclusion criteria: * pre-prp protocol refraction, fluorescein angiography, and optical coherence tomography and 7-14 day post-prp oct * ability to provide written informed consent and comply with study assessments for the full duration of the study * age 21 years or older * previously untreated pdr patients with high risk characteristics who develop edema within 7-14 days post prp therapy. this edema, determined by a masked investigator, will be characterized as either increased foveal thickness (\>10% increase from pre-prp foveal thickness), and/or increased macular volume on oct (\>10% increase from pre-prp macular volume). exclusion criteria: * pregnancy (positive pregnancy test) prior to enrollment in the study * any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated. * participation in another simultaneous medical investigation or trial * pre-prp clinically significant diabetic macular edema (csme) that would make the patient eligible for macular laser prior to prp * neovascularization of the iris or neovascular glaucoma * increased central foveal thickness for any other reason * concurrent macular diseases that could confound the results of this study * prior vitrectomy in the study eye * prior treatment with intravitreal injection including pegaptanib sodium, ranibizumab, bevacizumab or triamcinolone acetonide

Keywords: ranibizumab proliferative diabetic retinopathy macular edema following panretinal photocoagulation safety and efficacy intravitreal injection
endoscopic sleeve gastroplasty for morbid obesity

Conditions: Endoscopic Sleeve Gastroplasty

Summary: obesity and its related metabolic disorders are increasingly a heavy health burden to many parts of the world. weight control is a well-known important step in avoiding type 2 diabetes mellitus (t2dm). it is also an essential component for normalizing the blood glucose and preventing macrovascular and microvascular insults to patients with diagnosed t2dm. however, life-style modification, physical exercise and dietary adjustment are ineffective measures which are unlikely to confer adequate and sustainable weight loss for the truly obese. on the other hand, large scale long-term follow-up studies have confirmed the role of bariatric surgery in providing durable weight loss and remarkable improvement on medical comorbidities. among all the bariatric operations, laparoscopic sleeve gastrectomy (lsg) is currently the most widely adopted procedure worldwide because of its simplicity and effectiveness in weight reduction. however, lsg is not without risk. staple-line hemorrhage, leakage and stenosis are potentially life-threatening complications. lsg is also costly because of the need for expensive laparoscopic staplers.

a new endoscopic bariatric therapy, namely endoscopic sleeve gastroplasty (esg), has recently been proposed as a non-surgical procedure for the management of obesity with or without diabetes mellitus. preliminary data based on single arm series or phase ii studies have reported promising short and intermediate term weight control effect. however, whether esg is a feasible option comparable to lsg in the intermediate term remains an unanswered question. in addition, physical and functional outcomes after esg were not well documented in most of the reported series. realizing there is a knowledge gap in applying esg to patients with morbid obesity, we propose to study and compare the efficacy of weight control and functional outcomes of esg against conventional lsg. through this prospective randomized trial, the safety profiles, quality of life and changes in fasting and post-prandial gut hormone secretion after the two procedures will also be assessed and compared. the evidence thus generated shall lay a scientific foundation for esg which may become an alternative choice for patients who have concerns about complication and irreversibility of most bariatric surgery.

Eligibility criteria:
inclusion criteria: 1. a bmi \> 35 kg/m2 2. a bmi \> 30 kg/m2 with t2dm 3. a bmi\>3 30kg/m2 with 2 or more co-morbidities exclusion criteria: 1. significant anaesthetic risk (\> asa iii) 2. history of diabetic ketoacidosis or hyperosmolar coma 3. uncontrolled t2 dm with hba1c \> 12% 4. a bmi \> 45 kg/m2 5. malignancy diagnosed within 5 years 6. endoscopic findings of any pre-neoplastic/neoplastic lesions, portal hypertensive gastropathy or significant varices 7. chronic renal failure requiring dialysis 8. previous upper abdominal surgery (including bariatric surgery) affecting gastroduodenal configuration 9. major psychiatric illness including major depression and substance abuse 10. pregnancy or ongoing breast-feeding 11. inmates
comparison of anca and anti-gbm auto-antibodies removal kinetics between plasma exchanges and immunoadsorption in patients with anca-associated vasculitis or anti-gbm disease

Conditions: Kidney Failure, Acute

Summary: anti-neutrophil cytoplasmic antibodies (anca), directed against myeloperoxidase (mpo) and against proteinase 3 (pr3), have a pathogenic role during anca (aav) vasculitis. glomerular basement membrane (mbg) antibodies also have a direct pathogenic role in goodpasture's syndrome and anti-mbg antibody glomerulonephritis (gn). in some patients, the severity of renal and / or pulmonary involvement justifies the rapid purification of these autoantibodies by an apheresis procedure, while waiting for the effect of immunosuppressive treatments aimed at reducing their production. during vasculitis, plasma exchange (pe) is recommended in patients with severe renal impairment or intra-alveolar hemorrhage (2012 kdigo clinical practice guideline for glomerulonephritis). given certain disadvantages related to plasma exchanges (low volume of purified plasma, non-selective technique for immunoglobulins (ig), need for replacement solute, induction of coagulation disorders), immunoadsorption (ia), already used in transplantation, has been developed in these indications. ia has indeed greater selectivity for ig with a probable better purification capacity due to higher volumes of plasma treated per session. the price of ia is however higher than that of ep. these two apheresis techniques, ep and ia, are commonly used in france during severe forms of vasculitis anca or anti-mbg, without the superiority of one or the other has been demonstrated. as a result of higher plasma volumes being purified, ai may allow faster purification of pathogenic antibodies. no studies to date have specifically compared the purification kinetics of these antibodies between ep and ia. the cinevas study (vascularite antibody purification cinetic) is a multicentric pilot study whose main objective is to compare the purification kinetics of anca (anti-mpo or anti-pr3) and / or anti- mbg in patients treated with ep versus those treated with ia


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * patient with anca vasculitis with positive anti-mpo or anti-pr3 antibodies, or patient with goodpasture syndrome or anti-mbg antibody glomerulonephritis * patient for whom the investigating physician retains the indication of apheresis * induction treatment with corticosteroids and cyclophosphamide or rituximab exclusion criteria: * pregnancy or breastfeeding * vasculitis without anti-mpo, anti-pr3 or anti-mbg * severe anemia (hemoglobin \<7 g / dl) contraindicates additional blood sampling
interdisciplinary group care for the treatment of endometriosis-associated pain

Conditions: Endometriosis; Pelvic Pain

Summary: the goal of this clinical trial is to determine if peer empowered endometriosis pain support (peeps), an 8-week interdisciplinary, integrative group care program, decreases pain interference in participants with endometriosis-associated chronic pelvic pain between the ages 18 and 48. the main question we aim to answer is: is peeps more effective than education in decreasing pain interference? researchers will compare people receiving peeps plus usual care to those receiving education plus usual care to see if people participating in peeps demonstrate improvements in pain, physical function, and quality of life. participants will: * complete baseline quality of life surveys * participate in an 8-session group care program * provide feedback on each session and the program globally * complete follow up quality of life surveys at peeps completion, 6- and 12-months post-completion. * a sub-set will complete semi-structured interviews or focus groups about the experience of participating in peeps


Eligibility criteria:
inclusion criteria: * age 18-48 years * operative confirmation of endometriosis * chronic pelvic pain (pain perceived to originate from the pelvis, not exclusively during menses, lasting ≥6 months) * no plan to have surgery before or during the peeps cohort * able to attend at least six of the eight 2-hour weekly sessions on the washington university campus * comfort reading and speaking english as groups and materials are in english exclusion criteria: * currently pregnant * severe physical impairment (limiting yoga participation) * history of hip or spine surgery given increased risk of harm and need for extensive activity modification * current or history of psychiatric disorder with psychosis in order to minimize risk of adverse mental health effects to participants * opioid use ≥ 5 days in the past 3 months, other than for the 6-week post-operative period * history of surgical removal of bilateral ovaries

Keywords: group care integrative care pelvic floor physical therapy mindfulness patient-centered outcomes
music therapy as a tool for anxiety reduction in localized breast cancer

Conditions: Anxiety; Breast Cancer; Chemotherapy

Summary: breast cancer is the number one cancer in women worldwide, with 58,500 new cases in metropolitan france in 2018. the announcement of the cancer, the treatment methods and their side effects can generate unpleasant emotions, such as fear, for example, and the resources for coping with them differ according to the patient. coming to the hospital as an outpatient for chemotherapy is in itself a source of anxiety. the use of music in the treatment process is a therapy that can help patients to reduce the intensity of their unpleasant emotions. active music therapy involves the patient playing an instrument, including voice and body movement in rhythm, without requiring any musical skills. the presence of a qualified music therapy professional is essential, particularly in the reception of the emotions that may be generated during the sessions. these sessions can be collective or individual. in breast cancer, music therapy has been shown to be effective in reducing pain, anxiety, depressive symptoms and length of hospitalisation in patients undergoing mastectomy.


Eligibility criteria:
inclusion criteria: * patient with localized breast cancer * indication for adjuvant or neoadjuvant chemotherapy * patient \> 18 years of age * patient with signed consent * patient affiliated to a social security scheme exclusion criteria: * metastatic patient * triple negative patient * patient not eligible for curative surgery * patient who has already received chemotherapy * unaided deaf patient * women who are pregnant, likely to be pregnant or breastfeeding * a patient presenting a depressive episode or a psychotic pathology at the time of the initial consultation * patient who does not understand french * cognitive disorder or inability to understand, * patient protected by law, under court protection, guardianship or curatorship
efficacy and safety of idp-121 and idp-121 vehicle lotion in the treatment of acne vulgaris

Conditions: Acne

Summary: the objective of this study was to evaluate the efficacy, safety, and tolerability of a once daily topical application of idp-121 lotion compared with its vehicle (idp-121 vehicle lotion) in participants with moderate to severe acne vulgaris (acne) (that is, acne having an evaluator's global severity score \[egss\] of 3 \[moderate\] or 4 \[severe\]).


Eligibility criteria:
key inclusion criteria: * male or female at least 9 years of age and older. * written and verbal informed consent must be obtained. participants less than age of consent must sign an assent for the study and a parent or a legal guardian must sign the informed consent (if participant reaches age of consent during the study they should be re-consented at the next study visit). * participants must be willing to comply with study instructions and return to the study center for required visits. participants under the age of consent must be accompanied by the parent or legal guardian at the time of assent/consent signing. * if a cleanser, moisturizer or sunscreen is needed during the study, participants must be willing to use only allowed cleansers, moisturizers, sunscreens, or moisturizer/sunscreen combination products. if the participant wears makeup they must agree to use non-comedogenic makeup. key exclusion criteria: * use of an investigational drug or device within 30 days of enrollment or participation in a research study concurrent with this study. * any dermatological conditions on the face that could interfere with clinical evaluations such as acne conglobata, acne fulminans, secondary acne, perioral dermatitis, clinically significant rosacea, gramnegative folliculitis. * any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive. * participants with a facial beard or mustache that could interfere with the study assessments. * history of hypersensitivity or allergic reactions to any of the study preparations as described in the investigator's brochure, including known sensitivities to any dosage form of tretinoin. * participants who are unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function. * participants with any underlying disease that the investigator deems uncontrolled, and poses a concern for the participant's safety while participating in the study.
study on the occurrence of possible relapses and on the quality of life in patients who underwent turbk.

Conditions: Non Muscle Invasive Bladder Cancer; Non-Muscle Invasive Bladder Neoplasms; Non-Muscle Invasive Bladder Urothelial Carcinoma; Bladder Cancer; Bladder Disease; Bladder Neoplasm; Bladder Urothelial Carcinoma; Bladder Cancer Stage I, With Cancer in Situ; Bladder Cancer Recurrent; Bladder Urothelial Carcinoma in Situ; Bladder Urothelial Dysplasia

Summary: a database has been created and will be used in which data will be collected in electronic format relating to adult patients who underwent one of the following endoscopic resection surgeries: turbk, mapping, turbk second look, bladder biopsies.

each patient will be followed for approximately 10 years starting from the date of surgery. the patient may be contacted for yearly follow-up through one of the preferred methods indicated (phone call, email or home address) which will be carried out by the staff of the urology department. the data for each patient will then be transferred to the database itself. the data collected will be handled follwing the most strict gcps and privacy norms. the data entered will concern: * period before hospitalization (symptoms, clinical data) and completion of a pre-surgery questionnaire * hospitalization period with all its related data * questionnaires relating to quality of life which will be administered to the patient once a year according to the preferred method expressed by the patient in the informed consent.

Eligibility criteria:
inclusion criteria: * 18 years or older * patients with non-muscle invasive bladder cancer * indication to cancer removal through endoscopic resection surgery * ability to read and sign the informed consent exclusion criteria: * age \<18 years * inability to read and sign the informed consent

Keywords: intravescical therapies bladder urothelial carcinoma bladder neoplasm bladder disease bladder cancer intravesical instillations
safety and efficacy study of bms-908662 in combination with ipilimumab in subjects with advanced melanoma

Conditions: Melanoma

Summary: the purpose of the study is to identify a safe and tolerable dose of bms-908662 in combination with ipilimumab; and then to evaluate the anti-tumor response to bms-908662 when administered in combination with ipilimumab.


Eligibility criteria:
inclusion: * male and female subjects ≥ 18 years of age with a histologic or cytologic diagnosis of stage iii or stage iv (unresectable) melanoma * enrollment to cohort expansion will be limited to only those subjects whose tumors demonstrate the b-raf v600e mutation * ecog ≤ 1 * adequate organ \& marrow function exclusion: * uncontrolled or significant cardiovascular disease * cohort expansion: prior therapy with a raf inhibitor
gip effects at insulin induced hypoglycemia in patients with type 2 diabetes

Conditions: Type 2 Diabetes Mellitus

Summary: investigation of gip effects at fasting and hypoglycemia


Eligibility criteria:
inclusion criteria: * caucasians 18 years or older with type 2 diabetes (who criteria) exclusion criteria: * hba1c \>9 % * liver disease (alat/asat \>2 x upper normal limit) * diabetic nephropathy (s-creatinine \>130 µm or albuminuria) * proliferative diabetic retinopathy (anamnestic) * severe arteriosclerosis or heart failure (nyha group iii og iv) * anemia * treatment with medication not applicable to pause for 12 hours * fasting plasma glucose \>15 mm on screening day.